Skip to content
SPACListing
Browse
ScreenerFilingsMarketDeadlinesSponsorsBanksSectorsLearnPricingWatchlist
Pre-IPO

CANCER CAPITAL CORP

CIK 0001130889

Cash in trust

Not yet disclosed

Trust per share

Redemption value

IPO

Combination deadline

Not disclosed

Filings on record

110

Latest Mar 31, 2025

Overview

CANCER CAPITAL CORP is a special purpose acquisition company incorporated in Wyoming and registered with the SEC under CIK 0001130889. The vehicle is sponsored by CANCER. Registration statement on file; units not yet trading.

SEC filing history

Free tier: filings older than 24 hours
  • NT 10-K

    Late annual report notification

    Accession 0001554795-25-000078

    Mar 31, 2025

    1y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-24-000317

    Nov 21, 2024

    1y ago

    Open filing
  • NT 10-Q

    Late quarterly report notification

    Accession 0001554795-24-000296

    Nov 15, 2024

    1y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-24-000204

    Aug 14, 2024

    2y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-24-000126

    May 9, 2024

    2y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001554795-24-000087

    Apr 15, 2024

    2y ago

    Open filing
  • NT 10-K

    Late annual report notification

    Accession 0001554795-24-000075

    Apr 2, 2024

    2y ago

    Open filing
  • 8-K/A

    FORM 8-K/A

    Items 4.01, 9.01 · Accession 0001554795-24-000045

    Mar 12, 2024

    2y ago

    Open filing
  • 8-K

    Current report

    Items 4.01, 9.01 · Accession 0001554795-24-000032

    Mar 4, 2024

    2y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-23-000336

    Nov 2, 2023

    2y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-23-000237

    Aug 3, 2023

    3y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-23-000131

    May 3, 2023

    3y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001554795-23-000097

    Mar 29, 2023

    3y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-22-000364

    Nov 3, 2022

    3y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-22-000287

    Aug 12, 2022

    4y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-22-000184

    May 13, 2022

    4y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001554795-22-000107

    Mar 22, 2022

    4y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-21-000381

    Nov 5, 2021

    4y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-21-000281

    Aug 13, 2021

    5y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-21-000187

    May 17, 2021

    5y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001554795-21-000089

    Mar 25, 2021

    5y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-20-000286

    Nov 6, 2020

    5y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-20-000201

    Aug 10, 2020

    6y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-20-000121

    May 12, 2020

    6y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001554795-20-000101

    Apr 14, 2020

    6y ago

    Open filing
  • NT 10-K

    Late annual report notification

    Accession 0001554795-20-000076

    Mar 30, 2020

    6y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-19-000371

    Nov 12, 2019

    6y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-19-000236

    Aug 9, 2019

    7y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001554795-19-000125

    May 10, 2019

    7y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001554795-19-000061

    Mar 19, 2019

    7y ago

    Open filing

CANCER CAPITAL CORP: questions answered

What is CANCER CAPITAL CORP?

CANCER CAPITAL CORP is a special purpose acquisition company incorporated in Wyoming and registered with the SEC under CIK 0001130889. The vehicle is sponsored by CANCER. Registration statement on file; units not yet trading.

How much does CANCER CAPITAL CORP hold in trust?

No trust balance has been disclosed in a filing we have indexed for CANCER CAPITAL CORP. For a newly priced IPO this is normal: the figure first appears in the quarterly report after closing.

When must CANCER CAPITAL CORP complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if CANCER CAPITAL CORP does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in CANCER CAPITAL CORP, and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

Is the trust value the same as the share price for CANCER CAPITAL CORP?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

Who sponsors CANCER CAPITAL CORP, and what is their track record?

CANCER is the sponsor entity, part of the CANCER franchise. This is the only vehicle we have attributed to that sponsor.

Is CANCER CAPITAL CORP a good investment?

That is not a question this site answers. CANCER CAPITAL CORP is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this CANCER CAPITAL CORP data come from?

Filings CANCER CAPITAL CORP submitted to the SEC under CIK 0001130889: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Sep 4, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.